Skip to main content

Korro Bio, Inc.

KRRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001703647

In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 8 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Korro Bio, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of KRRO: Q1 2021 compared with Q2 2021
MeasureQ1 2021Of which not filed for Q2 2021Q2 2021Change
Holders115191−23
Shares19.7M200.0K19.6M+13.8K (+0.1%)
Value$186.6M$1.90M$193.9M+$9.15M (+5.0%)

1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (12)

Institutions that held Korro Bio, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to KRRO in Q2 2021
InstitutionSharesValue% of portfolio
Amundi776,088$7.73M0.01%
Sphera Funds Management Ltd.275,160$2.74M0.26%
Two Sigma Advisers, LP164,100$1.63M0.00%
Occudo Quantitative Strategies LP29,047$289.0K0.04%
Winton Group Ltd14,261$142.0K0.01%
Invesco Ltd.12,202$121.0K0.00%
Centaurus Financial, Inc.10,030$100.0K0.01%
Quantbot Technologies LP3,200$31.0K0.00%
US Bancorp2,105$21.0K0.00%
Parisi Gray Wealth Management702$7.00K0.00%
Hartford Financial Management Inc.500$5.00K0.00%
Global Financial Private Client, LLC40$3700.00%

Sold out (35)

Institutions that held Korro Bio, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.

Not filed for Q2 2021 yet (1)

Institutions that held Korro Bio, Inc. at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding KRRO in Q1 2021 that haven't filed for Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Amundi Asset Management US, Inc.200,024$1.90M